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Huntington disease (HD) reflects the dominant consequences of a CAG-repeat expansion in HTT. Analysis of common SNP-based hap-
lotypes has revealed that most European HD subjects have distinguishable HTT haplotypes on their normal and disease chromosomes
and that ~50% of the latter share the same major HD haplotype. We reasoned that sequence-level investigation of this founder haplo-
type could provide significant insights into the history of HD and valuable information for gene-targeting approaches. Consequently, we
performed whole-genome sequencing of HD and control subjects from four independent families in whom the major European HD
haplotype segregates with the disease. Analysis of the full-sequence-basedHTT haplotype indicated that these four families share a com-
mon ancestor sufficiently distant to have permitted the accumulation of family-specific variants. Confirmation of new CAG-expansion
mutations on this haplotype suggests that unlike most founders of human disease, the common ancestor of HD-affected families with
the major haplotype most likely did not have HD. Further, availability of the full sequence data validated the use of SNP imputation to
predict the optimal variants for capturing heterozygosity in personalized allele-specific gene-silencing approaches. As few as ten SNPs are
capable of revealing heterozygosity inmore than 97% of EuropeanHD subjects. Extension of allele-specific silencing strategies to the few
remaining homozygous individuals is likely to be achievable through additional known SNPs and discovery of private variants by com-
plete sequencing of HTT. These data suggest that the current development of gene-based targeting for HD could be extended to person-
alized allele-specific approaches in essentially all HD individuals of European ancestry.Introduction
Huntington disease (HD [MIM: 143100]) is a dominantly
inherited neurodegenerative disorder characterized by
involuntary movements, motor deficits, cognitive decline,
and psychiatric disturbance.1,2 The genetic cause of the
disease is expansion to over 35 units of a CAG trinucleotide
repeat in the coding sequence of huntingtin (HTT [MIM:
613004]).3 The HTT CAG repeat tract displays both germ-
line and tissue-specific somatic instability,4–7 but the size
of the CAG repeat inherited by an individual is the primary
determinant of the rate at which the pathogenic process
will lead to their clinical diagnosis.3,8–12 There is currently
no effective therapy for preventing the onset or delaying
the progression of HD, but there is considerable interest
in exploring gene-based approaches to suppress produc-
tion of mutant huntingtin mRNA or protein, given that
the dominant disease allele itself might be the most attrac-
tive target for effective therapeutic intervention.13 As part
of our ongoing effort to characterize HTT, we previously
defined the seven most frequent disease-associated HTT
haplotypes (here designated hap.01–hap.07) on European
HD chromosomes by using 20 common SNPs and one
indel (rs149109767 or delta2642: a 3 bp deletion allele at
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The Americanhaplotype, here referred to as hap.01, accounts for ~50%
of HD chromosomes among individuals of European
ancestry and that the region shared by about half of these
individuals extends to almost 1 Mb, consistent with a low
rate of recombination in the HTT region.14 The same
haplotype is less common among normal chromosomes
in that it accounts for approximately 9%.14 The eighth
most frequent HD-associated haplotype, designated here
as hap.08, is present on only ~2.1% of HD chromosomes
but is the most frequent HTT haplotype in the normal
European population in that it accounts for ~26.1% of con-
trol chromosomes. With respect to HD chromosomes,
there is a relatively strong founder effect, given that
hap.01, marked by the delta2642 deletion allele, is present
in ~50% of Europeans with HD. hap.05, the only
other frequent disease-associated haplotype bearing the
delta2642 deletion allele, comprises an additional ~5% of
disease chromosomes ancestrally related to hap.01, given
that they differ at only a single terminal SNP.14 We have
now completed a much finer-resolution characterization
of this major European HD haplotype by using complete-
sequence analysis to (1) fully define it at the nucleotide
level, (2) compare it between members of different
HD-affected families, (3) compare it to DNA sequences
from ancient Europeans, (4) contrast it with the mostMA 02114, USA; 2Program inMedical and Population Genetics, Broad Insti-
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Figure 1. Pedigree Structures of Four
Families Used for Haplotype Analysis
Four independent families in whom the
hap.01 haplotype segregates with disease
were analyzed by whole-genome sequenc-
ing followed by haplotype phasing. Of
the 38 individuals sequenced, 29 are
shown here, permitting the haplotype-
phasing analysis of 16 father-mother-child
trios (numbered by family and child; filled
and open symbols represent subjects with
an expanded HTT CAG repeat and normal
individuals, respectively). CAG repeats of
study subjects are provided under pedigree
symbols. Small CAG differences between
parent and child pairs (e.g.,52) are within
the margin of error of the CAG genotyping
assay, which takes the highest peak among
neighbor peaks as the repeat size of the
sample.common HTT haplotype on normal European chromo-
somes, and (5) provide foundational information for
investigating HTT-sequence-dependent allele-specific in-
terventions in HD.Material and Methods
Whole-Genome Sequencing
DNA samples of 38 individuals from four independent HD-
affected families (Figure 1) in whomhap.01 segregates with disease
were used for whole-genome sequencing at Complete Genomics,
which generated variant-calling files containing sequence variants
with confidence scores. Because we aimed to maximize SNP
discovery and the inclusion of related samples provided the oppor-
tunity to assess sequencing errors, we examined all variants origi-
nally reported by Complete Genomics.
Haplotyping by Trio Phasing
We performed haplotype phasing by using father-mother-child
trio data (summarized in Table 1). We phased the sequence across
HTT, plus 10 kb flanking regions at both 50 and 30 ends (chr4:
3,066,408–3,255,687; hg19 assembly, UCSC Genome Browser).
Trios with a HD parent, normal spouse, and HD or normal child
were identified in each family. In some cases, the same parents
were members of different trios because full siblings were
analyzed. Data pre-processing and trio phasing were performed
for each trio independently. In brief, a site (i.e., genetic locus)
was eliminated in a given trio if (1) genotypes in all three individ-
uals were unknown, (2) all three individuals were identically het-
erozygous, or (3) a Mendelian error was detected. Because we
aimed to maximize SNP coverage, we included sites with partially
missing data even though this makes detection of Mendelian
errors difficult. Thus, detecting Mendelian errors was based on
checking the genotype data for the following: (1) variant sites
without any missing data, (2) sites with no missing data in the436 The American Journal of Human Genetics 97, 435–444, September 3, 2015child and one or two alleles missing in
only one parent, and (3) sites with one
allele missing in the child and none
missing in the parents. This detection
pipeline could still miss some Mendelianerrors as a result of missing genotypes, but these errors could be
further identified by subsequent merging of multiple phased hap-
lotypes in a given family. After removing sites with Mendelian
errors, sites that could not be confidently phased because of
missing genotypes, and sites heterozygous in all three members
of the trio, we phased the alleles at all remaining sites to produce
a detailed haplotype.
After data pre-processing, we phased trio genotype data by using
the BEAGLE program and further analyzed the HD chromosome
haplotypes. Depending on the number of trios in a given family,
we obtained multiple HD chromosome haplotypes, and we
merged these within each family to discover any inconsistent
alleles. Locations and numbers of Mendelian errors and inconsis-
tent alleles are summarized in Table 1 and Figure S4. For each fam-
ily, we then finalized the HD chromosome haplotype by (1) taking
alleles for sites with at least two phased allele calls, (2) assigning
‘‘N’’ to sites that were unphaseable or had a missing genotype or
Mendelian errors, and (3) assigning ‘‘?’’ to the inconsistent sites.
These procedures yielded phased haplotypes covering at least
98.5% of the bases in the region (summarized in Table 1). We
then compared the finalized HD chromosome haplotypes from
all four families to identify seven family-specific alleles. For
those seven sites, we examined allele frequency in Kaviar315
and performed validation experiments using Sanger sequencing
or SNP genotyping. Four of these seven SNPs (rs141511796,
rs187059132, rs144933628, rs2798226) were known, and three
were not present in dbSNP, the 1000 Genomes Project, or Kaviar3.
The latter (rs776711851, rs750632134, and rs765413190) were
submitted to NCBI dbSNP for release in build 144.
Comparison to Ancient European Genomes
We compared the consensus hap.01 haplotype sequence to 69
ancient European DNA samples16 for the 20 SNP sites called in
the latter within chr4: 3,066,408–3,255,687 (hg19). First, we
phased all samples from that study, including ancient andmodern
DNAs, for those 20 SNPs by using the MACH program in order to
Table 1. Summary of Haplotype Phasing
Number
of Trios Total Sites
All Missing
Sites
Sites of Mendelian
Errors
Unphaseable
Sites
Inconsistent
Sites Phased Sites
Family 1 5 189,280 1,016 21 3,282 3 187,363
(98.98%)
Family 2 4 189,280 1,087 2 3,246 2 186,505
(98.53%)
Family 3 3 189,280 940 6 789 3 187,582
(99.10%)
Family 4 4 189,280 858 39 1,691 11 187,540
(99.08%)
For a given family, phased haplotypes were generated for 189,280 contiguous sites (chr4: 3,066,408–3,255,687; hg19 assembly) in complete trios from Figure 1.
Missing sites were those not called in any trio member. Unphaseable sites were (1) variants heterozygous in all three trio members and (2) variants that could not
be phased because of missing genotypes. Inconsistent sites had different phased allele calls within a family.obtain haplotypes. Subsequently, we compared the phased haplo-
types of 69 ancient DNA samples to hap.01 alleles at those 20 SNP
sites.
Identification of Recombination Events
We applied haplotype phasing to the same trio data by using only
SNP sites without anymissing alleles to identify recombination on
the HD chromosome.We analyzed a 1.5Mb genomic region (chr4:
2,500,000–4,000,000). For a given family, we compared trans-
mitted disease chromosomes (i.e., those with an expanded CAG
in HTT) to identify discordant alleles. Discordance between alleles
on the disease chromosomes inherited by one sibling and those
inherited by the others indicates recombination on the parent’s
disease chromosome. When such a discordant site was identified
in a child, we compared the parent’s transmitted disease chromo-
some and non-transmitted normal chromosome, reconstructed
from genotypes of the concordant progeny, to the discordant
child’s inherited disease chromosome across the flanking region.
We examined sites heterozygous in the CAG-expanded parent to
localize the region of recombination. By this approach, we identi-
fied two recombination events and subsequently compared them
to HapMap recombination rates.
Analysis of SNP Heterozygosity
We analyzed SNP heterozygosity by using 1000 Genomes Project
imputed genotype data to determine the limit of applicability of
allele-specific gene silencing. 2,803 subjects were genotyped on
the Illumina HumanOmni2.5-8 v.1 array at the Center for
Inherited Disease Research. Study subjects included HD and
normal individuals from the Massachusetts General Hospital
collection and the PREDICT-HD study.17,18 Genotype data and
documents from quality-control analysis are available at dbGaP:
phs000371. In brief, we subjected original genotype data to
quality-control analysis to generate high-quality genotype data
(e.g., sample genotyping call rate > 95%, SNP genotyping call
rate > 95%, SNP minor allele frequency > 1%, and SNP Hardy-
Weinberg equilibrium p value > 0.000001). Subsequently, we
imputed genotypes by using 1000 Genomes Project data as a refer-
ence panel with the MACH and MINIMAC programs.19 SNPs with
high imputation quality (e.g., R2 value greater than 0.5) were
analyzed. Data for 620 SNPs from 2,405 unique HD subjects
(i.e., individuals with expanded CAG repeats) were analyzed for
heterozygosity in HTT. Starting from all data, we calculated
heterozygosity to identify the SNP that had the highest level ofThe Americanheterozygosity. We then excluded heterozygous individuals and
re-calculated heterozygosity to identify the SNP that displayed
the highest level of heterozygosity in the remaining individuals.
We repeated this iteration ten times to evaluate the discriminating
power and coverage for allele-specific gene silencing by (1) all
SNPs, (2) exon SNPs, and (3) intron SNPs.Results
Whole-Genome Sequencing of HD-Affected Families
To increase the resolution of hap.01 to the nucleotide level,
we sequenced the whole genomes of 38 members (29 sub-
jects with expanded HTT CAG repeats and nine normal
relatives) of four HD-affected families in whom hap.01 seg-
regates with disease. The 29 individuals used for haplotype
analysis by examination of trios are shown in Figure 1. We
compared polymorphisms in the genome sequences to
HapMap data for genetic evidence of the ancestry of these
families. As shown in the principal-component-analysis
plot (Figure S2), samples from all 38 individuals (black cir-
cles) co-localize with HapMap CEU (Utah residents with
ancestry from northern and western Europe from the
CEPH collection) samples (red circles) and TSI (Toscani in
Italia) samples (green circles), indicating that they are of
European ancestry. We assessed familial relationships by
using the program PLINK20 to calculate PI_HAT values,
which represent the proportion of genome sharing, for
all possible pairs of HD subjects. All reported familial rela-
tionships were consistent with estimated genome sharing.
Average intra-family PLINK PI_HAT values (Figure S3, gray
cells) ranged from 0.359 to 0.438, where variation reflects
differences in family structure. However, average inter-
family PLINK PI_HAT values were quite low (Figure S3,
white cells), indicating no evidence of close relationships
between any of the families.
A Shared Ancestral HTT Haplotype
We next selected the 189,280 bp DNA sequence spanning
HTT (chr4: 3,066,408–3,255,687) for phasing in father-
mother-child trios to determine haplotypes at base-pair
resolution. Across the four families, it was possible to assessJournal of Human Genetics 97, 435–444, September 3, 2015 437
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Figure 2. Sequence-Based Haplotype hap.01 Is Compared to the Human Reference Sequence
Site variant alleles shared by the independently established consensus hap.01 disease chromosomes of all four families were compared to
the reference genome, identifying 27 differential sites, all of which are reported in dbSNP. The HTT structure is based on GenBank:
NM_002111 and is depicted from left (50) to right (30) on the line (representing the genomic region); narrow and thickened segments
represent non-coding and coding portions of the mRNA, respectively. The locations of variant sites are based on the hg19 genome
assembly. ‘‘D’’ indicates a single-nucleotide deletion. The site noted in green is a synonymous coding variant, and a codon loss (three
consecutive ‘‘D’’ sites) is shown in red. All other variants are non-coding.16 unique trios (Figure 1). We performed data preprocess-
ing and haplotype phasing (see Material and Methods)
separately for each trio and then merged phased haplo-
types for all trios within a given family to finalize a fam-
ily-specific HD chromosome haplotype. For any given
trio, a small number of bases could not be phased because
of missing reads, Mendelian errors, or heterozygosity of all
three members. A small number of called variants also ap-
peared inconsistent between members of the same family,
as shown in Figure S4. Inconsistent sites were contributed
by (1) partially missing genotypes in the trio data for
phasing, (2) heterozygous genotypes in both parents and
a partially missing genotype in a child, (3) sequencing
errors, or (4) possible somatic mutations. Overall, we
were able to generate a confidently phased HD haplotype
that encompassed at least 98.5% of the bases in the region
in each of these four families (Table 1).
The four family-specific haplotypes were nearly iden-
tical, arguing strongly for a common ancestral origin.
Using only bases that were confidently phased in all four
families (185,636 sites, 98% coverage), we reconstructed
the shared founder haplotype and compared it with the
human reference sequence (hg19). Across HTT, 27 bases
(together defining 22 site variants listed in dbSNP) differed
between the hap.01 founder and the reference alleles
(Figure 2). The 22 site variants include a deletion of four in-
tronic bases, a deletion of three coding bases, and a gain of
three bases in hap.01, and 19 single-nucleotide changes.
Two of the differences (rs2857790 and the delta2642 indel
[rs14910767]) occurred in the coding sequence, three
occurred in the UTRs of the mRNA, and the remainder
occurred in non-mRNA sequences (introns and non-genic
flanking sequences). As in the reference sequence, in
hap.01 the proline-encoding trinucleotide repeat down-
stream of the polymorphic and expanded glutamine-
encoding CAG repeat consists of seven CCG units.21
Family-Specific Variants
Although the family-specific haplotypes were identical to
the consensus ancestral haplotype at almost all of the438 The American Journal of Human Genetics 97, 435–444, Septemb185,636 bases, they diverged from each other at seven
variant sites. We confirmed the existence of these seven
unexpected variants by additional Sanger sequencing and
genotyping (Figure S5). As shown in Figure 3, these sites
include three SNPs not present in dbSNP, the 1000
Genomes Project, or Kaviar3 (rs776711851, rs750632134,
and rs765413190), two rare (<1% minor allele frequency)
known SNPs (rs141511796 and rs187059132), and two
common SNPs (rs144933628 and rs2798226) located
downstream of the 30 UTR at the extreme centromeric
end of the haplotype. The accumulation (or loss in all
but one family) of variants in generations subsequent to
the haplotype founder could have occurred by several
mechanisms. The previously unidentified SNPs most likely
represent point mutations that occurred on the original
haplotype, whereas the known SNPs could have resulted
from either a recurrent mutation or a very limited segment
of gene conversion or double recombination. Whatever
the mechanism(s) of divergence, the most parsimonious
scenario for the relationships between the four family-
specific haplotypes is shown in Figure S6.
The accumulation of family-specific variants on an
otherwise identical haplotype suggested an ancient origin
for hap.01, so we examined recently reported genome-
wide SNP data that included 20 SNPs across HTT for 69
ancient Europeans.16 We found that a haplotype in one in-
dividual (Motala 2) from the Swedish Mesolithic culture,
dated at 5898–5531 cal BC (on the basis of direct radio-
carbon dates), was identical at all 20 SNPs with hap.01,
consistent with an ancient origin for this haplotype.
New CAG-Expansion Mutations
For most disorders associated with founder haplotypes, the
common ancestor possessed the disease-causing mutation.
For hap.01 in HD, however, the common ancestor most
likely did not carry an expanded CAG repeat, given that
several families carrying the delta2642 deletion allele
have been previously reported to exhibit de novo expan-
sion of a normal-length CAG allele to an expanded,
HD-producing CAG allele.22 Using SNP genotyping, weer 3, 2015
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Figure 3. Locations and Control-Population Frequencies of Family-Specific Variants
(A) The final hap.01 sequences revealed family-specific differences at seven sites, whose locations, genomic reference alleles, and disease-
chromosome alleles for each family are shown.
(B) Kaviar3 data were used for obtaining allele frequencies for the seven family-specific variants, shown as pie charts. In three cases,
alleles for variations not seen previously are shown at 0% frequency in the pie chart.confirmed in two available families that the ‘‘new’’ muta-
tion to an expanded HTT CAG-repeat length associated
with HD occurred on chromosomes containing either the
hap.01 or the related hap.05 haplotype (Figure S7), directly
documenting that the most common disease-associated
haplotype can be traced back in some circumstances to
recent non-HD progenitors.
Characterization of Recombination Landscape
Sequence-level haplotypes in multiple transmissions
within a family provide a rare opportunity for character-
izing the recombination patterns of the mutation-bearing
chromosome in HD subjects. We have previously noted
the sharing of extended haplotypes of 1 Mb or more in a
substantial fraction of HD individuals, so we analyzed a
broad region of 1.5 Mb of phased HD chromosome
sequence (chr4: 2,500,000–4,000,000, shown in Figure 4)
by comparing transmitted HD chromosome haplotypes
within a family to identify recombination events. As previ-
ously reported in multi-allele-marker linkage studies and
revealed by the HapMap recombination rate shown in
Figure 4A, the HTT region shows a relatively low recombi-
nation rate, arguing against crossovers subsequent to CAG
expansion as the source of the bulk of the diversity of HTTThe Americanhaplotypes observed on HD chromosomes.14 Proximal to
HTT, recombination rates increase and show a particular
hotspot at ~3,725,000 (expanded in Figure 4B). Of 16
meiotic transmissions of the disease chromosome in the
four HD-affected families, two exhibited recombination
events: one in family 1 and one in family 4. Both indepen-
dent events occurred within the same 3 kb segment of
DNA, at the hot-spot noted above (Figures 4C and 4D).
Although we examined only a limited number of meioses,
the sequence-level findings within and centromeric to
HTT suggest that the recombination landscape of hap.01
HD chromosomes is comparable to that of normal chro-
mosomes and is not dramatically disrupted by the pres-
ence of an expanded CAG repeat.
Potential for Allelic Discrimination in HD
One of the most promising avenues for exploration of HD
therapies is sequence-based silencing of the mutant allele,
at either the transcriptional or the translational level.
Given the potential for negative consequences of loss of
normal huntingtin activity, the ideal gene-silencing strat-
egy would be specific to the mutant allele. The capacity
to discriminate alleles depends not only on the disease
haplotype but also on the normal HTT haplotype withJournal of Human Genetics 97, 435–444, September 3, 2015 439
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Figure 4. Recombination Events on hap.01 HD Chromosomes
(A) RefSeq genes are indicated in blue arrows above the orange traces, which represent the HapMap recombination rates (chr4:
2,500,000–4,000,000 bp region). Recombination rates are very low around HTT, and recombination peaks are located centromerically.
The red arrow indicates the highest recombination peak in this region, where two recombination events were detected.
(B) In an expanded view of the highest recombination peak, the reference genomic coordinates with recombination rates are aligned
with actual recombination events in (C) and (D). Both recombination events were located within the recombination peak at chr4:
3,725,000 bp.
(C) A recombination event in family 1 is shown. Five transmitted HD chromosomes were compared for chr4: 22,500,000–4,000,000,
revealing a recombination event in the maternal transmission in trio 2. The mother’s disease chromosome (red) and normal chromo-
some (green) are compared to the transmitted disease chromosomes (red and green). Only bases at sites of heterozygosity are shown.
(D) A similar analysis to that in (C) was performed for family 4. One recombination event was detected in the paternal transmission
of trio 4.which it is paired in each individual. The most frequent
diplotype in European HD individuals naturally combines
the most frequent HD haplotype, hap.01, and the most
frequent haplotype in the normal population, hap.08,
which differ at 19 of 21 sites in the common-marker-based
haplotype (Figure S1). The presence of 12 hap.08 control
chromosomes in our fully sequenced families (three chro-
mosomes in family 1, three chromosomes in family 3, and
six chromosomes in family 4) permitted us to also compare
differences at the nucleotide level. We were able to
define 97.9% of all bases in hap.08 and discovered that
there were 109 differences between hap.01 and hap.08
(Figure S8). Interestingly, there were also 15 consistent dif-
ferences between the normal hap.08 chromosomes
defined in these three families, indicating that, like our
hap.01 HD chromosomes, these control chromosomes
have accumulated additional variants not found in440 The American Journal of Human Genetics 97, 435–444, Septembtheir shared ancestor. The extensive differences between
hap.01 and hap.08 offer numerous potential targets for
allele-specific gene silencing. However, this diplotype ac-
counts for only 10.4% of European HD individuals, indi-
cating the need for a personalized approach to extend
allele-specific gene-silencing strategies to the bulk of the
HD population.
Our data suggest that sequencing of other HTT haplo-
types could readily identify sites of genetic variation appli-
cable to allele-specific targeting for other diplotypes.
However, to estimate the potential coverage that could
already be achieved through known variants, we capital-
ized on genome-wide SNP array data from HD subjects
and 1000 Genomes Project data to impute the SNP varia-
tion across HTT in European HD individuals. We validated
the approach by comparing SNP variants imputed from
the array data for 24 family 1 and 2 individuals who wereer 3, 2015
Table 2. Allele Discrimination by Heterozygous SNPs
Round
Exon or Intron SNP Exon SNP Intron SNP
ID Percentage
Cumulative
Percentagea ID Percentage
Cumulative
Percentagea ID Percentage
Cumulative
Percentagea
1 rs11731237 52.6% 52.6% rs362307 47.5% 47.5% rs11731237 52.6% 52.6%
2 rs71597207 22.2% 74.9% rs2530595 23.8% 71.3% rs71597207 22.2% 74.9%
3 rs115335747 10.9% 85.8% rs362331 10.9% 82.2% rs187059132 10.1% 84.9%
4 rs3135055 5.4% 91.2% rs362267 3.6% 85.8% rs2530596 5.7% 90.6%
5 rs362312 1.9% 93.1% rs116419279 3.0% 88.8% rs362312 2.0% 92.6%
6 rs191103377 1.6% 94.7% rs35892913 2.0% 90.8% rs3135054 1.7% 94.3%
7 rs3135054 0.9% 95.6% rs115335747 1.6% 92.3% rs57666989 0.9% 95.2%
8 rs2530596 0.6% 96.2% rs2276881 0.6% 93.0% rs186403576 0.8% 96.0%
9 rs186403576 0.5% 96.7% rs146151652 0.5% 93.4% rs148125464 0.6% 96.5%
10 rs187059132 0.5% 97.1% rs144364475 0.4% 93.8% rs3135055 0.5% 97.0%
aThe cumulative percentage of HD subjects heterozygous for at least one SNP. The most frequent heterozygous SNP remaining was chosen in each round.also fully sequenced. For 405 imputed SNPs in the HTT re-
gion, we observed a median genotype concordance of
99%, suggesting that the use of imputed SNPs can provide
a relatively accurate assessment of heterozygosity in the
HD population.
To identify SNPs providing optimal discrimination of
HD and normal chromosomes in European HD subjects,
we sequentially selected the SNP that was heterozygous
in the maximum proportion of HD subjects, removed
those subjects from consideration, and again selected the
most heterozygous SNP. We repeated this process ten times
(Table S1). The results are shown in Table 2 for HTT as a
whole (chr4: 3,076,237–3,245,687; hg19), mRNA-specific
SNPs, and intron-specific SNPs, for each of which is pro-
vided a list of ten SNPs capable of supporting allele-specific
targeting because of their heterozygosity in 97.1%, 93.8%,
and 97.0% of HD subjects, respectively. Clearly, variants
already known to be polymorphic in the European popula-
tion can distinguish disease chromosomes from normal
chromosomes, allowing targeting of either the mRNA or
genomic sequence, in the vast majority of HD heterozy-
gotes. A very small percentage of HD subjects will be ho-
mozygous for each of these SNPs, but it is likely that going
further down the list of imputed SNPs and/or personalized
deep sequencing, as performed here for hap.01 and
hap.08, will reveal additional variants that could make
almost all HD individuals eligible for an allele-specific
gene-silencing approach.Discussion
Our sequence-level analysis of the major HD-associated
HTT haplotype supports the previous hypothesis from
HD haplotypes that multiple different origins of the
CAG-expansion mutation have contributed to the Euro-The Americanpean HD population.23 However, it also provides detailed
molecular support for a single ancestral chromosome
that contributes to 55% of HD subjects and thus represents
a strong founder effect. The fact that de novo CAG expan-
sions are observed from chromosomes with the same
ancestral haplotype but with CAG repeats below the HD-
producing size range indicates that the common ancestor
of today’s hap.01 HD subjects was most likely an individ-
ual with a CAG repeat in the normal range, unlike the
disease-producing mutations inherent to most other
haplotypes associated with human disease. In the pre-
sent-day population, a group of haplotypes clustered as
haplogroup A, which includes hap.01, are associated
with chromosomes that bear a higher-than-average pro-
portion of high-normal (27–35 CAGs) HTT CAG re-
peats,23 and it has been suggested that haplogroup Amight
be more prone to CAG-repeat instability. However, a direct
comparison of HTT CAG-repeat lengths on disease chro-
mosomes showed no significant difference between haplo-
types,14 and parent-child transmission data suggested that
the intergenerational HTT CAG-repeat instability, at least
of expanded alleles, is not restricted to specific haplotypes
(unpublished data). The same sequencing approach used
here could be applied to defining the origins of the other
HD-associated haplotypes that, unlike hap.05, do not
show evidence of a clear relationship with hap.01. For
example, hap.02 and hap.03 are present at comparable fre-
quencies on both disease and normal chromosomes, and
sequence-level analysis could potentially identify variants
that distinguish a subset of each that is enriched on disease
chromosomes.
Our analysis suggests that hap.01 existed in the Euro-
pean population at least 7,000 years ago and that today’s
HD individuals with an expanded CAG repeat on the
hap.01 haplotype share a common ancestor who could
be quite ancient but apparently had a normal-lengthJournal of Human Genetics 97, 435–444, September 3, 2015 441
CAG repeat. The sequence-level analysis of hap.01 indi-
cates that variants occurring subsequently to this ancestor
have contributed to the slight divergence of the original
haplotype over an extended time period. In comparing
four families in whom hap.01 segregates with disease, we
found seven unexpected SNP differences. The three previ-
ously unidentified SNPs are most likely due to point muta-
tions occurring at the average genome-wide mutation
rate,24 as would be expected for an ancient haplotype.
Although the two previously known rare SNPs could theo-
retically be present because of the same phenomenon,
their presence in non-HD individuals could reflect their
occurrence in an ancestor prior to CAG expansion or be
due to an inherently higher-than-average mutation rate
at that site. Alternatively, the alleles could have moved
onto hap.01 by some other mechanism (e.g., gene conver-
sion or local double recombination). The common SNPs
downstream of the HTT 30 UTR could theoretically have
been moved independently onto hap.01 by simple recom-
bination, although our examination of downstream SNPs
in the sequencing data does not provide unequivocal evi-
dence of such events. The possibility that rs2798226 and
rs144933628 have been introduced onto hap.01 as point
mutations would suggest a high mutation rate for these
sites, which is not consistent with their observed disequi-
librium patterns in control populations. Thus, like the
appearance of the two rarer SNPs, the presence of the
unexpected rs2798226 allele on hap.01 in family 1 could
have resulted from another mechanism. The unexpected
accumulation of these variants on a founder haplotype
suggests the intriguing possibility that, in addition to
de novo mutation, simple recombination, and structural
alteration, other mechanisms such as gene conversion or
double recombination contribute significantly to the
divergence of human chromosomal haplotypes between
individuals. Sequence-level analysis of manymore founder
haplotypes in human disease could provide a system for
exploring the relative importance of different mechanisms
in generating sequence variation on an initially fixed
background.
There is currently no disease-modifying treatment for
HD, but silencing the mutant allele by using any of a vari-
ety of technologies is an attractive route for potential inter-
vention because it would target the actual cause of disease
pathogenesis. However, for the continuing wellness of an
individual with HD, it might be important to preserve
wild-type HTT function. Consequently, an allele-specific
gene-targeting strategy is likely to be optimal, making it
critical to determine the frequency with which an HD indi-
vidual has distinguishable disease and normal HTT alleles
and to define the variants that provide this discrimination
in the highest proportion of HD subjects.23,25,26 From our
previous SNP-based definition of HTT haplotypes, the
seven most frequent HD-associated haplotypes account
for 83% of European disease chromosomes and 35% of
normal chromosomes.14 The extended haplotypes across
HTT are consistent with the very low recombination rate442 The American Journal of Human Genetics 97, 435–444, Septembobserved in the region. This low recombination rate also
predicts that the use of genotype data from a limited
number of SNPs should provide accurate imputation of
the large number of SNPs known to exist in the European
population. Our full-sequence analysis of the HTT region
permitted us to directly confirm this assumption, making
it possible to use imputed SNPs to assess heterozygosity
across the locus. Our data provide estimates of the fre-
quency of heterozygosity in European HD subjects for
1000 Genomes population variants and identify those
SNPs with the greatest discriminatory power between
HD and normal chromosomes, maximizing the potential
for allele-specific targeting approaches aimed at either
mRNA or genomic DNA. In the vast majority of cases,
the diplotype involves two different haplotypes, and
known SNPs can provide the basis for distinguishing be-
tween normal and CAG-expanded versions of HTT. In
the few remaining cases, personalized sequence analysis
is very likely to reveal a discriminating variant. Indeed,
in the families studied here, two HD individuals bear
two copies of the SNP-defined hap.01 haplotype, but
our full-sequence analysis revealed two sites with different
alleles on their HD and normal chromosomes. Overall,
our sequence-level haplotype analyses led to the encour-
aging conclusion that virtually all European HD individ-
uals are candidates for allele-specific gene-silencing
techniques in a personalized medicine approach and
suggest that a similar sequence-based strategy can be
readily applied to extend these techniques to other
populations.Accession Numbers
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